Drug Type Antibody |
Synonyms A composition containing one or more bispecific molecules targeting T cell receptor £ chain constant region (TRBC) |
Target |
Action inhibitors |
Mechanism CD3 inhibitors(T cell surface glycoprotein CD3 inhibitors), TRBC1 inhibitors(TRBC1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
T-Cell Leukemia | Preclinical | United States | 25 Aug 2022 | |
T-Cell Lymphoma | Preclinical | United States | 25 Aug 2022 |